As the BRAF V600E mutation very rarely occurs in LS-associated CRCs (1.4%) but is displayed by around 64% of sporadic MSI CRCs with MLH1 methylation [105], the proposed immunosuppressive features of this mutation have to be considered when comparing local immune responses in the two MSI CRC groups. This evidence concerns the gene BRAF and colorectal carcinoma.